Abtract. We hypothesized that adrenergic mechanisms support the postabsorptive plasma glucose concentration, and prevent hypoglycemia when glucagon secretion is deficient. Accordingly, we assessed the impact of glucagon deficiency, produced by infusion of somatostatin with insulin, without and with pharmacologic a-and f-adrenergic blockade on the postabsorptive plasma glucose concentration and glucose kinetics in normal human subjects. During somatostatin with insulin alone mean glucose production fell from 1.5±0.05 to 0.7±0.2 mg/kg per min and mean plasma glucose declined from 93±3 to 67±4 mg/dl over 1 h; glucose production then increased to base-line rates and plasma glucose plateaued at 64-67 mg/dl over 2 h. This plateau was associated with, and is best attributed to, an eightfold increase in mean plasma epinephrine. It did not occur when adrenergic blockade was added; glucose production remained low and mean plasma glucose declined progressively to a hypoglycemic level of45±4 mg/dl, significantly (P < 0.001) lower than the final value during somatostatin with insulin alone. These data provide further support for the concept that maintenance of the postabsorptive plasma glucose concentration is a function ofinsulin and glucagon, not of insulin alone, and that adrenergic mechanisms do not normally play a critical role. They indicate, however, that an endogenous adrenergic agonist, likely adrenomedullary epinephrine, compensates for deficient glucagon secretion and prevents hypoglycemia in the Address reprint requests to Dr. Cryer.
plasma glucose concentration and glucose kinetics in normal human subjects. During somatostatin with insulin alone mean glucose production fell from 1.5±0.05 to 0.7±0.2 mg/kg per min and mean plasma glucose declined from 93±3 to 67±4 mg/dl over 1 h; glucose production then increased to base-line rates and plasma glucose plateaued at 64-67 mg/dl over 2 h. This plateau was associated with, and is best attributed to, an eightfold increase in mean plasma epinephrine. It did not occur when adrenergic blockade was added; glucose production remained low and mean plasma glucose declined progressively to a hypoglycemic level of45±4 mg/dl, significantly (P < 0.001) lower than the final value during somatostatin with insulin alone. These data provide further support for the concept that maintenance of the postabsorptive plasma glucose concentration is a function ofinsulin and glucagon, not of insulin alone, and that adrenergic mechanisms do not normally play a critical role. They indicate, however, that an endogenous adrenergic agonist, likely adrenomedullary epinephrine, compensates for deficient glucagon secretion and prevents hypoglycemia in the
Introduction
The physiologic mechanisms of hypoglycemic glucose counterregulation-those that promote recovery from hypoglycemia-have been defined (1) (2) (3) (4) (5) (6) (7) . Glucose recovery is not due solely to dissipation of insulin. Glucagon plays a primary counterregulatory role; epinephrine compensates largely for deficient glucagon secretion. Glucose recovery fails to occur only in the absence of both glucagon and epinephrine. Although other hormonal factors, neural mechanisms, and hepatic autoregulation may be involved, they need not be invoked and are not sufficiently potent to promote recovery from hypoglycemia when the key counterregulatory hormones, glucagon and epinephrine, are deficient.
More recently it has been shown that the same principles apply to nonhypoglycemic glucose counterregulation-the physiologic mechanisms that blunt physiologic decrements in plasma glucose, prevent hypoglycemia, and restore or maintain euglycemia-in that they apply to regulation of the transition from exogenous glucose delivery to endogenous glucose production late after glucose ingestion (8, 9) .
There is considerable evidence, reviewed by Gerich (10, 1 1), that glucagon supports postabsorptive glucose production and, therefore, the postabsorptive plasma glucose concentration. Somatostatin suppresses glucagon (and insulin) secretion and causes an initial decrease in glucose production and plasma glucose. This effect ofsomatostatin is prevented by glucagon replacement. Further, the small decrement in plasma glucose that follows induction of glycosuria in dogs is converted to a substantial decrement when glucagon secretion is suppressed by somatostatin (12) . Despite decrements in plasma glucose, however, glucagon deficiency per se does not produce absolute hypoglycemia (10) (11) (12) (13) . On the other hand, adrenergic mechanisms do not support postabsorptive glucose production (2) in normal humans, and postabsorptive plasma glucose concentrations are not discernibly reduced in epinephrine-deficient (adrenalectomized) persons (3, 9) .
Thus, maintenance of the postabsorptive plasma glucose concentration is a coordinated function ofinsulin and glucagon, adrenergic mechanisms do not normally play a critical role, and epinephrine compensates for deficient glucagon secretion in hypoglycemic glucose counterregulation and in at least one example ofnonhypoglycemic glucose counterregulation. Therefore, we hypothesized that adrenergic mechanisms support the postabsorptive plasma glucose concentration and prevent hypoglycemia when glucagon secretion is deficient. In an initial study (13) we found that combined a-and f3-adrenergic blockade blunts the late increase in glucose production and plasma glucose that follows their initial decrease during combined insulin and glucagon deficiency produced by infusion of somatostatin. Adrenergic blockade did not, however, result in a progressive decline in plasma glucose. We reasoned that this was because insulin secretion, as well as that ofglucagon, was suppressed. Therefore, we assessed the impact of glucagon deficiency produced by infusion of somatostatin with insulin, without and with pharmacologic adrenergic blockade on the postabsorptive plasma glucose concentration and glucose kinetics in normal human subjects.
Methods
10 normal human subjects (six women and four men), whose ages ranged from 18 to 33 yr and who were within 15% of ideal body weight, gave their informed, written consent to participate in this study, which was approved by the Washington University Human Studies Committee. We performed the study at the Washington University General Clinical Research Center.
After an overnight fast, subjects assumed the supine position, which was maintained throughout. Intravenous followed with addition of infusions of propranolol (Inderal; Ayerst Laboratories, New York, NY, in a dose of 0.08 mg/min after 5.0 mg over 2 min, and phentolamine (Regitine; Ciba-Geigy Corp., Pharmaceuticals Div., Summit, NJ), in a dose of 0.5 mg/min after 5.0 mg over 2 min, from -30 through 180 min. The sequence ofstudies was varied randomly. Blood samples were drawn, and the blood pressure and heart rate recorded, at 10-min intervals from -60 through 180 min.
Plasma glucose was determined with a glucose oxidase method and plasma glucose appearance and disappearance rates were calculated from the specific activities of tritiated glucose (14, 15) . Plasma insulin (16), C-peptide (17) , glucagon (18) , growth hormone (19) , and cortisol (20) were measured by radioimmunoassay. Antiserum 30K was used to measure glucagon and an antiserum purchased from Calbiochem-Behring Corp. (La Jolla, CA) to measure C-peptide. Plasma epinephrine and norepinephrine were measured with a single isotope derivative assay (21) employing 50-gl samples. Detection limits were 3.1 MU/ml for insulin, 1.0 ng/ml for C-peptide, 45 pg/ml for glucagon, 0.4 ng/ml for growth hormone, 3.0 yg/dI for cortisol, and 10 pg/ml for both epinephrine and norepinephrine. Blood alanine (22) , lactate (23) , glycerol (24), and f3-hydroxybutyrate (24) were measured with microfluorometric enzymatic techniques.
The data (mean±SE) were analyzed with a t test for paired data.
Results
During infusion of somatostatin with insulin the mean plasma glucose concentration declined from 93±3 to 67±4 mg/dl at 60 min, but then plateaued at 64-67 mg/dl. The 1 80-min value was 64±4 mg/dl, not significantly different from the 60-min value. The initial decline (91±3-67±4 mg/dl at 60 min) was similar during somatostatin with insulin coupled with propranolol plus phentolamine. However, plasma glucose did not plateau, but rather declined progressively to a 180-min value of 45±4 mg/dl, significantly (P < 0.001) lower than the 180-min value of 64±4 mg/dl during somatostatin with insulin alone.
The points comprising the glucose curves, illustrated in Fig. 1 , were significantly different from 100 through 180 min. There were no consistent symptoms during somatostatin with insulin. Symptoms such as hunger and diaphoresis occurred in all subjects during somatostatin with insulin and propranolol plus phentolamine; impaired mentation, a mandatory stop point, occurred in two subjects. For data analysis the last value for each parameter from these two subjects was used in the calculation of later means.
Somatostatin with insulin resulted in an initial fall in glucose production (plasma glucose appearance rate, Ra) from 1.5±0.05 mg/kg per min to a nadir of 0.7±0.2 mg/kg per min at 50 min ( Fig. 1 ). Glucose production then rose to approximate basal rates from 70 through 180 min. There were no changes in glucose utilization (plasma glucose disappearance rate, Rd). The initial fall in glucose production (from 1.5±0.1 mg/kg per min to a nadir of 0.6±0.2 mg/kg per min at 40 min) was similar during somatostatin with insulin coupled with propranolol plus phentolamine. However, the subsequent rise in glucose production was markedly attenuated; mean rates remained below base line and were significantly (P < 0.05) lower than during somatostatin with insulin alone by 80 min (Fig. 1) . Again, there were no changes in glucose utilization. Thus, the progressive decline in the plasma glucose concentration was the result of reduced glucose production.
Plasma concentrations of potentially important glucoregulatory factors are also shown in Fig. 1 . Plasma C-peptide, insulin, and glucagon concentrations were comparable under both study conditions. Plasma C-peptide was suppressed by 65-70% and plasma growth hormone was suppressed by 70-80%, indicating the efficacy of the infused somatostatin. These represent minimum estimates of the degree of suppression since C-peptide and growth hormone levels were suppressed to levels below the sensitivity of the assays in most of the subjects. yg/dl, significantly (P < 0.01) higher than the corresponding than the correspon Figure 1 . Mean (±SE) plasma glucose concentrations, plasma glucose appearance rates and plasma disappearance rates, and plasma concentrations of C-peptide, insulin, glucagon, growth hormone, cortisol, epinephrine, and norepinephrine during infusions of somatostatin (SRIF) with insulin alone, filled circles, and during infusions of somatostatin (SRIF) with insulin plus propranolol (PRP) and phentolamine (PTL), open circles, in 10 normal human subjects.
1/dl during somatostatin with insulin alone.
tedly the result of substantially lower plasma tions during the former study (33) . nine concentrations rose more than eightfold, 3±33 pg/ml (P < 0.01) at 180 min, during insulin. Plasma epinephrine levels reached < 0.001) at 90 min and remained elevated r increments in epinephrine in response to Ls in plasma glucose have been reported prelaboratory (33) . Plasma norepinephrine conincreased, from 156±11 to 271±29 pg/ml g somatostatin with insulin, although the ingradual than that of epinephrine. The first higher than base line was 231±22 pg/ml (P a. As shown in Fig. 1 , propranolol plus phenalter plasma epinephrine concentrations sigreased plasma norepinephrine levels from I1 pg/ml (P < 0.01) before initiation of sonsulin. Phentolamine is known to increase rine (35) , which is likely the result ofincreased ease due to presynaptic a2-adrenergic receptor coupled with reflex sympathetic activation nall decrease in blood pressure produced by below). Further, propranolol decreases the ,holamines from the circulation (36). Protolamine markedly enhanced the plasma catses to decrements in plasma glucose during insulin. Plasma epinephrine rose to a 180-)±510 pg/ml, significantly (P < 0.01) higher iding value of 153±33 pg/ml during soma-tostatin with insulin alone. Plasma norepinephrine rose to a 180-min value of 1,060±225 pg/ml, significantly (P < 0.01) higher than the corresponding value of 271±29 pg/ml during somatostatin with insulin alone.
Blood concentrations of metabolic intermediates are shown in Fig. 2 . During somatostatin with insulin alone blood lactate rose from 770±84 to a peak of 1,095±136 ,mol/liter (P < 0.02) at 130 min; this rise did not occur during somatostatin with insulin coupled with propranolol plus phentolamine (683±60-817±53 umol/liter). Blood alanine rose from 303±23 to a peak of 347±29 umol/liter (P < 0.05) at 150 min during somatostatin with insulin alone and similarly, from 285±23 to 338±23 'mol/ liter (P < 0.02) during somatostatin with insulin coupled with propranolol plus phentolamine. Blood glycerol declined from 83±6 to a nadir of 55±7 ,mol/liter (P < 0.02) at 40 min and then rose to 89±21 ,umol/liter at 160 min during somatostatin with insulin alone. In contrast, during somatostatin with insulin coupled with propranolol plus phentolamine, blood glycerol declined progressively from 84±9 to 64±9 ,mol/liter at 40 min, to 39±5 ,umol/liter at 160 min, (P < 0.05 vs. the control value of 89±21 umol/liter). Blood fl-hydroxybutyrate levels declined from 128±21 to 75±5 jimol/liter (P < 0.02) at 60 min and remained at about that level thereafter during somatostatin with insulin alone; similar changes (114±13 to 66±4 ,mol/liter) occurred during somatostatin with insulin coupled with propranolol plus phentolamine.
As shown in Table I , there were no significant changes in heart rate or blood pressure during somatostatin with insulin alone although heart rate tended to rise. During somatostatin with insulin coupled with propranolol plus phentolamine, mean heart rates, systolic blood pressures, and diastolic blood pressures were significantly lower than those during somatostatin with insulin alone. 
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Discussion
These data document that adrenergic mechanisms, likely mediated by adrenomedullary epinephrine, support the postabsorptive plasma glucose concentration, and prevent hypoglycemia, when glucagon secretion is suppressed, insulin is present, and plasma glucose levels are lowered in normal human subjects.
There is considerable evidence that glucagon normally supports postabsorptive glucose production and functions in concert with insulin to maintain the postabsorptive plasma glucose concentration (10, 11, 13) . The present studies were not designed to reassess this concept, but the findings are consistent with it. The dose of insulin (200 uU/kg per min) that we infused with somatostatin was a compromise. Ideally, we would have wished to produce isolated glucagon deficiency by infusing somatostatin with insulin in a dose sufficient to maintain portal insulin concentrations at base-line levels. That is, of course, impractical with peripheral venous infusions. Thus, we selected an insulin dose that, when infused with somatostatin, produced mild peripheral venous hyperinsulinemia and portal venous insulin levels that can be estimated (from the measured peripheral insulin levels at base line and during infusions and from the degree of C-peptide suppression) to be approximately twothirds of base-line levels. Nonetheless, the initial decrease in glucose production and plasma glucose, with no increase in glucose utilization, provide biologic evidence of isolated glucagon deficiency. Thus, we produced greater initial decrements in plasma glucose than did Sacca et al. (37) despite the fact that they infused larger doses of insulin and did not suppress endogenous insulin (or glucagon) secretion and thus produced peripheral venous insulin levels -25% higher (the difference in portal venous insulin levels may well have been greater) than those in the present study. Nonetheless, the latter data clearly underscore the fact that moderate hyperinsulinemia can result in decrements in plasma glucose despite normal glucagon secretion. Since such glucose decrements do not result in hypoglycemia (37), effective glucose counterregulatory systems must be operative. The present data indicate that these include epinephrine as well as glucagon and that other hormonal, neural, or autoregulatory mechanisms need not be invoked.
After an initial decrease, glucose production rose to approximate basal rates and mean plasma glucose plateaued at 64-67 mg/dl over 2 h despite ongoing suppression of glucagon secretion. Thus, a factor in addition to glucagon must support the postabsorptive plasma glucose concentration, at least when glucagon secretion is deficient and plasma glucose levels are lowered. The finding of temporally related increments in plasma epinephrine suggests that that factor is an adrenomedullary discharge. This suggestion is supported by the results of the study with pharmacologic adrenergic blockade.
The plateau of plasma glucose that occurred during glucagon deficiency produced by somatostatin with insulin did not occur when glucagon deficiency was produced during combined aand fi-adrenergic blockade with propranolol and phentolamine. Rather, mean plasma glucose declined progressively to a hypoglycemic level, 45 mg/dl. This decline was the result ofreduced glucose production. Insulin and glucagon levels were comparable during both studies. Thus, adrenergic mechanisms support postabsorptive glucose production and the plasma glucose concentration, and prevent hypoglycemia, when glucagon secretion is deficient. Although these adrenergic mechanisms could be activated by norepinephrine released from sympathetic nerves, it is far more likely that they are activated by adrenomedullary epinephrine for three reasons. First, the plasma glucose plateau during somatostatin with insulin alone was temporally associated with a more than eightfold increase in mean plasma epinephrine to a level known to have hyperglycemic effects in man (38) . In contrast, the increment in plasma norepinephrine was small and occurred considerably later. Second, in both hypoglycemic glucose counterregulation (1-7) and in another model of nonhypoglycemic glucose counterregulation (9), adrenomedullary epinephrine, but not sympathetic neural norepinephrine, compensates for deficient glucagon secretion. Third, measurements of sympathetic activity by means of tissue norepinephrine turnover in rats (39, 40) have shown that hypoglycemia suppresses, rather than stimulates, the activity of the sympathetic nervous system. Insulin-induced hypoglycemia fails to produce an increase in plasma norepinephrine in persons who have undergone bilateral adrenalectomy (3), indicating that the small increment seen in normal subjects is the result of norepinephrine release from the adrenal medullae rather than from sympathetic nerves. Thus, it is adrenomedullary epinephrine, rather than sympathetic neural norepinephrine, that supports the postabsorptive plasma glucose concentration when glucagon is deficient. The kinetic data indicate that this is largely the result of an epinephrineinduced increase in glucose production. However, epinephrine is known to both stimulate glucose production and limit glucose utilization (41) . The present data do not exclude an additional effect of epinephrine on glucose utilization during glucagon deficiency.
Increments in blood lactate and blood glycerol, indices of glycolysis and lipolysis, respectively, occurred during glucagon deficiency. These changes were prevented by combined adrenergic blockade and provide further evidence ofbiologically active epinephrine release in response to the plasma glucose decrements produced by glucagon deficiency. In summary, maintenance ofthe postabsorptive plasma glucose concentration is a coordinated function of insulin and glucagon, not ofinsulin alone, in man. Adrenergic mechanisms do not normally play a critical role. However, epinephrine compensates for deficient glucagon secretion and prevents hypoglycemia. Thus, postabsorptive hypoglycemia occurs when both glucagon secretion and epinephrine are deficient and insulin is present. Although other hormonal, neural, or autoregulatory counterregulatory factors may be involved in maintenance of the postabsorptive plasma glucose concentration, they need not be invoked and they are not sufficiently potent to prevent postabsorptive hypoglycemia when the key glucose counterregulatory hormones, glucagon and epinephrine, are deficient.
This synthesis should not be interpreted to suggest that the counterregulatory function ofepinephrine is limited to glucagondeficient states. It is quite conceivable that epinephrine prevents hypoglycemia when sustained hyperinsulinemia or other glucose-lowering factors are sufficient to overcome the counterregulatory actions ofglucagon and result in a decrement in plasma glucose. We would suggest, as an operational model, that small fluctuations in plasma glucose are regularly modulated by insulin and glucagon, whereas more substantial decrements in plasma glucose, regardless of their initiating mechanism, elicit adrenomedullary secretion and that epinephrine in concert with glucagon blunts the glucose decrements and prevents hypoglycemia.
These data indicate that maintenance of a level of plasma glucose adequate for normal cerebral function, and thus essential for survival, is accomplished by redundant defenses against hypoglycemia. Postabsorptive hypoglycemia does not occur during deficiency ofeither glucagon (1O, 1 1, present data) or epinephrine (2, 3, 9, 13) alone, nor during combined deficiency of glucagon and epinephrine when insulin secretion is also suppressed (13) . Hypoglycemia due to glucoregulatory abnormalities occurs only when both glucagon and epinephrine are deficient and insulin is present or insulin levels are high enough to overwhelm counterregulatory mechanisms. The presence of redundant defenses against the development of postabsorptive hypoglycemia accounts for the ability of many insulin-treated patients with insulin-dependent diabetes mellitus to maintain their plasma glucose at levels sufficient for normal cerebral function despite hyperinsulinemia and deficient glucagon responses, as well as the susceptibility to hypoglycemia of those patients in whom epinephrine secretion is also deficient (7) .
Thus, the principles of hypoglycemic glucose counterregulation (1-7) and those of nonhypoglycemic glucose counterregulation in both the postprandial (8, 9) and the postabsorptive states are fundamentally the same. Counterregulation is not due solely to dissipation of insulin. Glucagon plays a primary counterregulatory role, whereas epinephrine compensates largely for deficient glucagon secretion; epinephrine may also compensate for insufficient glucagon action. Counterregulation fails, and hypoglycemia occurs, when both glucagon and epinephrine are deficient and insulin is present.
